BLUF is in public beta. Automated sourcing and summaries by the BLUF engine, monitored by our team. Summaries may contain errors — verify important details at the source. Not medical, legal or financial advice. Public beta — automated summaries may contain errors. Full disclaimer
BLUFSOURCED EVENT BRIEFLAST CHANGED Nov 10, 2026, 9:01 PM
DRUGS, DEVICES & RECALLS • UNITED STATES
FDA approves asundexian for secondary stroke prevention
1 SOURCES UNITED STATESNEW
NOT MEDICAL ADVICE
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
BLUF
The FDA approved asundexian (Sunharbo) for secondary stroke prevention, according to MedPage Today. The supplied report describes it as the first approved factor XIa inhibitor but does not provide the full indication or trial details.
HOW THIS BRIEF WAS MADE 1 outlet: 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections
Why it matters
The approval adds a reported medication option in the United States for secondary stroke prevention. The article does not provide enough detail to assess how many patients may be eligible or how the drug compares with existing treatments.
What happens next
The report does not give the full prescribing indication, availability details or further regulatory steps.
The complete FDA indication and prescribing information
Further details on the evidence supporting the approval